PacBio Teams Up with NCCS to Revolutionize Cancer Research
PacBio (NASDAQ: PACB), renowned for developing high-quality, precise sequencing solutions, has secured an exciting new partnership with the National Cancer Centre of Singapore (NCCS). This partnership aims to spearhead advancements in cancer research by harnessing PacBio's cutting-edge sequencing technologies, notably the Onso short-read sequencing platform. Together, they will profile the genomic landscape of prevalent cancers in Asia, paving the way for improved diagnoses and treatments.
Focus on Cancer Genomics with Onso Technology
The collaboration will center around analyzing prevalent cancers in Asia utilizing the Onso short-read sequencing system coupled with Kinnex long-read sequencing kit. The spotlight will be on single-cell RNA sequencing, which allows for a detailed exploration of the genetic factors influencing cancer development. Onso’s impressive accuracy in short-read sequencing positions it as an essential tool for detecting mutations tied to various cancer types, including gastrointestinal stromal tumors (GIST). This powerful platform will facilitate in-depth analyses, potentially leading to breakthroughs in cancer diagnostics and therapeutic strategies.
Empowering Local Cancer Research
As part of this partnership, DKSH, PacBio’s authorized channel partner in Asia, has successfully installed the Onso platform at the Cancer Discovery Hub within NCCS. This hub is pivotal in fostering cancer research and advancing discovery initiatives. The outcomes from this collaboration promise to not only benefit Singapore but also extend access to the state-of-the-art technology for the wider Asian research community. By aligning with DKSH, PacBio reinforces its dedication to enhancing local cancer genomics research.
Multi-Omics Approach to Cancer Analysis
By integrating Revio's long-read sequencing capabilities with the Onso platform, researchers will embark on comprehensive multi-omics studies. This collaboration will examine transcript isoforms and genetic variations at the single-cell level, enabling an exhaustive analysis of cancer genomes. The synergistic use of Onso for short reads and Revio for long reads offers a thorough understanding of cancer's genetic intricacies, thereby introducing new avenues for precision oncology.
Voices from the Collaboration
Asst Prof Jason Chan, who leads the Cancer Discovery Hub at NCCS, expressed enthusiasm about the partnership, stating, “We are thrilled to join forces with PacBio in this endeavor that combines short-read and long-read sequencing technologies. This collaboration will allow us to explore the complex genetic underpinnings of cancer types common in Asia, which ultimately aims to enhance patient-specific diagnostic and treatment strategies.”
Additionally, Jason Kang, General Manager and Vice President at PacBio APAC, highlighted the company’s commitment to advancing cancer research. He remarked, “With the Onso platform being established through the support of our partner DKSH, we are excited to bring our innovative sequencing solutions to the research community, empowering scientists to uncover new insights in cancer biology.”
About PacBio
PacBio (NASDAQ: PACB) stands out as a major player in the life sciences technology sector, focusing on the design, development, and manufacturing of premier sequencing solutions tailored to tackle the complexities of genetic research. The company operates utilizing two distinctive core technologies, ensuring high accuracy, quality, and completeness in sequencing applications. Their offerings span human germline sequencing, oncology, infectious diseases, and numerous scientific inquiries aimed at addressing genetic complexities. Interested parties can learn more about PacBio by visiting their official website.
Frequently Asked Questions
What is the main goal of the PacBio and NCCS collaboration?
The collaboration primarily aims to enhance cancer research in Asia by utilizing PacBio's advanced sequencing technologies to better understand the genetic landscape of prevalent cancers.
Which sequencing technologies are being used in this partnership?
The partnership will utilize the Onso short-read sequencing platform and Kinnex long-read sequencing kit, focusing on single-cell RNA sequencing to profile cancer genomes.
How will this collaboration benefit the research community?
The collaboration is expected to provide cutting-edge sequencing technology to both Singapore and the broader Asian research community, enhancing capabilities in cancer genomics research.
What is the significance of the Cancer Discovery Hub?
The Cancer Discovery Hub serves as a pivotal facility for cancer research and discovery, enabling scientists to explore genomic complexities and advance diagnostic and treatment options for cancer.
What is PacBio's vision for cancer research?
PacBio's vision is to empower researchers with advanced sequencing solutions that unlock new insights into cancer biology, ultimately leading to improved patient outcomes through tailored diagnostics and treatments.
